SpyGlass Pharma Inc.
Organization details
- Legal name
- SpyGlass Pharma Inc.
- Former names
- SpyGlassPharma, Inc. SpyGlass Ophthalmics, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 3841 — Surgical & Medical Instruments & Apparatus
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Irvine
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- SGP
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001778922
- EIN
- 83-3044245
Board of directors
- Since 2026
-
Bilal Arshad Khan · DirectorSince 2026
-
Elizabeth G. O'Farrell · DirectorSince 2026
-
Geoffrey B. Pardo · DirectorSince 2026
- Since 2026
-
Kirk G. Nielsen · DirectorSince 2026
-
Malik Y. Kahook · Director · See remarksSince 2026
-
Michael Dybbs · DirectorSince 2026
-
Patrick H. Mooney · Director · Chief Executive OfficerSince 2026
- Since 2026
- Since 2026
-
Zachary Scheiner · DirectorSince 2026
Chief executives
Board connections
9 of this board's directors also sit on 35 other boards. 35 are in the same sector.
-
Nkarta Inc. Same sectorvia Ali Behbahani, Michael Dybbs, Peter Kolchinsky, Rajeev M. Shah and Zachary Scheiner
-
Black Diamond Therapeutics Inc. Same sectorvia Ali Behbahani, Peter Kolchinsky and Rajeev M. Shah
-
Jade Biosciences Inc. Same sectorvia Habib J. Dable, Peter Kolchinsky and Rajeev M. Shah
-
LENZ Therapeutics Inc. Same sectorvia Peter Kolchinsky, Rajeev M. Shah and Zachary Scheiner
-
PepGen Inc. Same sectorvia Habib J. Dable, Peter Kolchinsky and Rajeev M. Shah
-
Tyra Biosciences Inc. Same sectorvia Habib J. Dable, Peter Kolchinsky and Rajeev M. Shah
-
ARS Pharmaceuticals Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Acrivon Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Acumen Pharmaceuticals Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Artiva Biotherapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Bambusa Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Bicara Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
CVRx Inc. Same sectorvia Ali Behbahani and Kirk G. Nielsen
-
Climb Bio Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Evommune Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Freenome Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Hemab Therapeutics Holdings Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Janux Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Mineralys Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Parabilis Medicines Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Septerna Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Sionna Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Solid Biosciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Vor Biopharma Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Wave Life Sciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Werewolf Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
CRISPR Therapeutics AG Same sectorvia Ali Behbahani
-
Geron Corporation Same sectorvia Elizabeth G. O'Farrell
-
Kalaris Therapeutics Inc. Same sectorvia Michael Dybbs
-
Korro Bio Inc. Same sectorvia Ali Behbahani
-
LENSAR Inc. Same sectorvia Elizabeth G. O'Farrell
-
Monte Rosa Therapeutics Inc. Same sectorvia Ali Behbahani
-
Relay Therapeutics Inc. Same sectorvia Habib J. Dable
-
Shoulder Innovations Inc. Same sectorvia Geoffrey B. Pardo
-
Sutro Biopharma Inc. Same sectorvia Michael Dybbs
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $221,480,000
- 17 purchases by 15 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 9, 2026 | RA Capital Healthcare Fund LP Director, 10% owner | Derivative conversion | +2,524,473 | — | — |
| Feb 9, 2026 | Ali Behbahani Director, 10% owner | Derivative conversion | +1,619,240 | — | — |
| Feb 9, 2026 | Florence Anthony A. Jr. 10% owner | Derivative conversion | +1,619,240 | — | — |
| Feb 9, 2026 | BASKETT FOREST 10% owner | Derivative conversion | +1,619,240 | — | — |
| Feb 9, 2026 | NEA 17 GP, LLC 10% owner | Derivative conversion | +1,619,240 | — | — |
| Feb 9, 2026 | Yang Rick 10% owner | Derivative conversion | +1,619,240 | — | — |
| Feb 9, 2026 | Makhzoumi Mohamad 10% owner | Derivative conversion | +1,619,240 | — | — |
| Feb 9, 2026 | Scott D. Sandell 10% owner | Derivative conversion | +1,619,240 | — | — |
| Feb 9, 2026 | Edward T. Mathers 10% owner | Derivative conversion | +1,619,240 | — | — |
| Feb 9, 2026 | Carmen Chang 10% owner | Derivative conversion | +1,619,240 | — | — |
| Feb 9, 2026 | Walker Paul Edward 10% owner | Derivative conversion | +1,619,240 | — | — |
| Feb 9, 2026 | Geoffrey B. Pardo Director | Derivative conversion | +1,875,013 | — | — |
| Feb 9, 2026 | Bilal Arshad Khan Director | Open-market purchase | +20,000 | $16.00 | $320,000 |
| Feb 9, 2026 | Kirk G. Nielsen Director | Derivative conversion | +1,690,230 | — | — |
| Feb 9, 2026 | Vensana Capital I GP, LLC 10% owner | Derivative conversion | +1,690,230 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about SpyGlass Pharma Inc.
Who is the CEO of SpyGlass Pharma Inc.?
Patrick H. Mooney has been SpyGlass Pharma Inc.'s Chief Executive Officer since February 2026.
How many directors are on SpyGlass Pharma Inc.'s board?
SpyGlass Pharma Inc.'s board has 12 directors: Ali Behbahani, Bilal Arshad Khan, Elizabeth G. O'Farrell, Geoffrey B. Pardo, Habib J. Dable, Kirk G. Nielsen, Malik Y. Kahook, Michael Dybbs, Patrick H. Mooney, Peter Kolchinsky and 2 others.
Are SpyGlass Pharma Inc. insiders buying or selling shares?
Over the last 12 months, SpyGlass Pharma Inc. insiders bought $221.5 million of shares in 17 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="spyglass-pharma-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.